Silence Therapeutics plc

08/21/2019 | Press release | Distributed by Public on 08/21/2019 03:29

Additional Listing

Additional listing

August 21, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ('Silence' or 'the Company') a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 100,000 new ordinary shares of 5p each ('New Ordinary Shares') following the exercise of share options under the Employee Share Option Scheme.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on August 28, 2019. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 78,094,027. The Company holds no shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.


Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

Tel: +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

Tel: +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

Tel: +44 (0) 20 3709 5700


Westwicke Partners

Peter Vozzo

[email protected]

Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: